{"topic_id":"ade_tigilanol_tiglate_adverse_events","category":"ade","context":"---\ntopic_id: ade_tigilanol_tiglate_adverse_events\ncategory: ade\ntitle: \"FDA ADE reports for Tigilanol Tiglate (active ingredient) — total reports, species & reaction breakdown\"\nlang: en\nsource: \"openFDA animalandveterinary/event.json (FDA CVM adverse event reports), pulled 2026-07-22\"\nsource_file: pdf-raw/ade/ade_active_ingredients_2026-07-22_b10.json\ndate_parsed: 2026-07-22\ntokens_estimated: 376\nverification:\n  method: substring_match\n  claims: 32\n  passed: 32\n  date: 2026-07-22\n---\n\n# Tigilanol Tiglate — FDA Animal & Veterinary Adverse Event (ADE) Reports\n\nSource: openFDA `animalandveterinary/event.json`, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Tigilanol Tiglate is a active ingredient.\n\n## Total reports\nTigilanol Tiglate: 1998\n\n## Reports by species (top entries)\n- Dog 1974\n- Human 9\n- Horse 5\n- Cat 2\n- Other 1\n\n## Top reported reactions (VEDDRA terms, top entries)\n- Lack of efficacy - NOS 853\n- Injection site swelling 688\n- Wound 400\n- Injection site pain 298\n- Pain NOS 290\n- Swelling NOS 285\n- Injection site necrosis 233\n- Swollen limb 223\n- Injection site complication NOS 214\n- Injection site bruising 206\n\nSource JSON: `pdf-raw/ade/ade_active_ingredients_2026-07-22_b10.json` (openFDA animalandveterinary/event.json, pulled 2026-07-22).\n","sources":[],"tokens_estimated":254,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}